Skip to main content
Top
Published in: Hereditary Cancer in Clinical Practice 1/2012

Open Access 01-12-2012 | Research

BRAF mutations in thyroid tumors from an ethnically diverse group

Authors: Hans-Juergen Schulten, Sherine Salama, Zuhoor Al-Mansouri, Reem Alotibi, Khalid Al-Ghamdi, Osman Abdel Al-Hamour, Hassan Sayadi, Hosam Al-Aradati, Adel Al-Johari, Etimad Huwait, Mamdooh Gari, Mohammed Hussain Al-Qahtani, Jaudah Al-Maghrabi

Published in: Hereditary Cancer in Clinical Practice | Issue 1/2012

Login to get access

Abstract

Background

The molecular etiology of thyroid carcinoma (TC) and other thyroid diseases which may present malignant precursor lesions is not fully explored yet. The purpose of this study was to estimate frequency, type and clinicopathological value of BRAF exon 15 mutations in different types of cancerous and non-cancerous thyroid lesions originating in an ethnically diverse population.

Methods

BRAF exon 15 was sequenced in 381 cases of thyroid lesions including Hashimoto´s thyroiditis, nodular goiters, hyperplastic nodules, follicular adenomas (FA), papillary TC (PTC), follicular variant PTC (FVPTC), microcarcinomas of PTC (micro PTC; tumor size ≤ 1 cm), follicular TC (FTC), and non-well differentiated TC (non-WDTC).

Results

We identified BRAF mutations in one of 69 FA, 72 of 115 (63%) PTC, seven of 42 (17%) FVPTC, 10 of 56 (18%) micro PTC, one of 17 (6%) FTC, and one of eight (13%) non-WDTC. Most of the cases showed the common V600E mutation. One case each of PTC, FVPTC, and FTC harbored a K601E mutation. A novel BRAF mutation was identified in a FA leading to deletion of threonine at codon 599 (p.T599del). A rare 3-base pair insertion was detected in a stage III PTC resulting in duplication of threonine at codon 599 (p.T599dup). Patients with PTC harboring no BRAF mutation (BRAFwt) were on average younger than those with a BRAF mutation (BRAFmut) in the PTC (36.6 years vs. 43.8 years). Older age (≥ 45 years) in patients with PTC was significantly associated with tumor size ≥ 4 cm (P = 0.018), vessel invasion (P = 0.004), and distant metastasis (P = 0.001). Lymph node (LN) involvement in PTC significantly correlated with tumor size (P = 0.044), and vessel invasion (P = 0.013). Of notice, taken the whole TC group, family history of thyroid disease positively correlated with capsular invasion (P = 0.025).

Conclusions

Older age is manifold associated with unfavorable tumor markers in our series. The K601E identified in a PTC, FVPTC, and FTC seems to be more distributed among different histological types of TC than previously thought. The T599del is a yet undescribed mutation and the rare T599dup has not been reported as a mutation in PTC so far.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61: 69–90. 10.3322/caac.20107CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61: 69–90. 10.3322/caac.20107CrossRefPubMed
2.
go back to reference Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, Shah JP, Fremgen AM, Stewart AK, Holzer S: Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 2000, 89: 202–217. 10.1002/1097-0142(20000701)89:1<202::AID-CNCR27>3.0.CO;2-ACrossRefPubMed Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, Shah JP, Fremgen AM, Stewart AK, Holzer S: Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study. Cancer 2000, 89: 202–217. 10.1002/1097-0142(20000701)89:1<202::AID-CNCR27>3.0.CO;2-ACrossRefPubMed
4.
go back to reference Smallridge RC, Marlow LA, Copland JA: Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009, 16: 17–44.CrossRefPubMed Smallridge RC, Marlow LA, Copland JA: Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009, 16: 17–44.CrossRefPubMed
5.
go back to reference Qari FA: Pattern of thyroid malignancy at a University Hospital in Western Saudi Arabia. Saudi Med J 2004, 25: 866–870.PubMed Qari FA: Pattern of thyroid malignancy at a University Hospital in Western Saudi Arabia. Saudi Med J 2004, 25: 866–870.PubMed
6.
go back to reference Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al.: Mutations of the BRAF gene in human cancer. Nature 2002, 417: 949–954. 10.1038/nature00766CrossRefPubMed Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al.: Mutations of the BRAF gene in human cancer. Nature 2002, 417: 949–954. 10.1038/nature00766CrossRefPubMed
7.
go back to reference Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, et al.: BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005, 90: 6373–6379. 10.1210/jc.2005-0987CrossRefPubMed Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, et al.: BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005, 90: 6373–6379. 10.1210/jc.2005-0987CrossRefPubMed
8.
go back to reference Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116: 855–867. 10.1016/S0092-8674(04)00215-6CrossRefPubMed Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116: 855–867. 10.1016/S0092-8674(04)00215-6CrossRefPubMed
9.
go back to reference Trovisco V, Vieira de Castro I, Soares P, Maximo V, Silva P, Magalhaes J, Abrosimov A, Guiu XM, Sobrinho-Simoes M: BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004, 202: 247–251. 10.1002/path.1511CrossRefPubMed Trovisco V, Vieira de Castro I, Soares P, Maximo V, Silva P, Magalhaes J, Abrosimov A, Guiu XM, Sobrinho-Simoes M: BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004, 202: 247–251. 10.1002/path.1511CrossRefPubMed
10.
go back to reference Nucera C, Goldfarb M, Hodin R, Parangi S: Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim Biophys Acta 2009, 1795: 152–161.PubMed Nucera C, Goldfarb M, Hodin R, Parangi S: Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim Biophys Acta 2009, 1795: 152–161.PubMed
11.
go back to reference : Thyroid. In AJCC Cancer Staging Manual. 7th edition. Edited by: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. Springer, New York; 2010:87–96. : Thyroid. In AJCC Cancer Staging Manual. 7th edition. Edited by: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. Springer, New York; 2010:87–96.
12.
go back to reference DeLellis RA, Williams ED: Thyroid and parathyroid tumors. In Pathology and genetics of tumours of endocrine organs (IARC WHO classification of tumours). Edited by: DeLellis RA, Lloyd RV, Heitz PU, Eng C. IARC Press, Lyons; 2004:51–56. DeLellis RA, Williams ED: Thyroid and parathyroid tumors. In Pathology and genetics of tumours of endocrine organs (IARC WHO classification of tumours). Edited by: DeLellis RA, Lloyd RV, Heitz PU, Eng C. IARC Press, Lyons; 2004:51–56.
13.
go back to reference Schulten HJ, Al-Maghrabi J, Al-Ghamdi K, Salama S, Al-Muhayawi S, Chaudhary A, Hamour O, Abuzenadah A, Gari M, Al-Qahtani M: Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma. Anticancer Res 2011, 31: 4179–4183.PubMed Schulten HJ, Al-Maghrabi J, Al-Ghamdi K, Salama S, Al-Muhayawi S, Chaudhary A, Hamour O, Abuzenadah A, Gari M, Al-Qahtani M: Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma. Anticancer Res 2011, 31: 4179–4183.PubMed
15.
go back to reference Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S, Ibrahim M, Al-Nuaim A, Ahmed M, Amin T, Al-Fehaily M, et al.: Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab 2008, 93: 611–618. 10.1210/jc.2007-1717CrossRefPubMed Abubaker J, Jehan Z, Bavi P, Sultana M, Al-Harbi S, Ibrahim M, Al-Nuaim A, Ahmed M, Amin T, Al-Fehaily M, et al.: Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab 2008, 93: 611–618. 10.1210/jc.2007-1717CrossRefPubMed
16.
go back to reference Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, et al.: BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 2008, 15: 191–205. 10.1677/ERC-07-0212CrossRefPubMed Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, et al.: BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer 2008, 15: 191–205. 10.1677/ERC-07-0212CrossRefPubMed
17.
go back to reference Lee JH, Lee ES, Kim YS: Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007, 110: 38–46. 10.1002/cncr.22754CrossRefPubMed Lee JH, Lee ES, Kim YS: Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007, 110: 38–46. 10.1002/cncr.22754CrossRefPubMed
18.
go back to reference Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, et al.: Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 2006, 13: 455–464. 10.1677/erc.1.01086CrossRefPubMed Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, et al.: Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 2006, 13: 455–464. 10.1677/erc.1.01086CrossRefPubMed
19.
go back to reference Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, Garcia-Rostan G: BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2008, 68: 618–634. 10.1111/j.1365-2265.2007.03077.xCrossRef Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, Garcia-Rostan G: BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2008, 68: 618–634. 10.1111/j.1365-2265.2007.03077.xCrossRef
20.
go back to reference Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B, Griffin A: The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007, 246: 466–470. discussion 470–461 10.1097/SLA.0b013e318148563dCrossRefPubMedPubMedCentral Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B, Griffin A: The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007, 246: 466–470. discussion 470–461 10.1097/SLA.0b013e318148563dCrossRefPubMedPubMedCentral
21.
go back to reference Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, et al.: BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003, 88: 5399–5404. 10.1210/jc.2003-030838CrossRefPubMed Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, et al.: BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003, 88: 5399–5404. 10.1210/jc.2003-030838CrossRefPubMed
22.
go back to reference Kim KH, Kang DW, Kim SH, Seong IO, Kang DY: Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004, 45: 818–821.CrossRefPubMed Kim KH, Kang DW, Kim SH, Seong IO, Kang DY: Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004, 45: 818–821.CrossRefPubMed
23.
go back to reference Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F: BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008, 93: 3943–3949. 10.1210/jc.2008-0607CrossRefPubMed Elisei R, Ugolini C, Viola D, Lupi C, Biagini A, Giannini R, Romei C, Miccoli P, Pinchera A, Basolo F: BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008, 93: 3943–3949. 10.1210/jc.2008-0607CrossRefPubMed
24.
go back to reference Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P, Basolo F: Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007, 92: 4085–4090. 10.1210/jc.2007-1179CrossRefPubMed Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P, Basolo F: Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007, 92: 4085–4090. 10.1210/jc.2007-1179CrossRefPubMed
25.
go back to reference So YK, Son YI, Park JY, Baek CH, Jeong HS, Chung MK: Preoperative BRAF mutation has different predictive values for lymph node metastasis according to tumor size. Otolaryngol Head Neck Surg 2011, 145: 422–427. 10.1177/0194599811404649CrossRefPubMed So YK, Son YI, Park JY, Baek CH, Jeong HS, Chung MK: Preoperative BRAF mutation has different predictive values for lymph node metastasis according to tumor size. Otolaryngol Head Neck Surg 2011, 145: 422–427. 10.1177/0194599811404649CrossRefPubMed
26.
go back to reference Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S: Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003, 88: 4393–4397. 10.1210/jc.2003-030305CrossRefPubMed Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S: Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003, 88: 4393–4397. 10.1210/jc.2003-030305CrossRefPubMed
27.
go back to reference Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ, Shong YK: The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2005, 63: 588–593. 10.1111/j.1365-2265.2005.02389.xCrossRef Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ, Shong YK: The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2005, 63: 588–593. 10.1111/j.1365-2265.2005.02389.xCrossRef
28.
go back to reference Frau DV, Lai ML, Caria P, Dettori T, Coni P, Faa G, Morandi L, Tallini G, Vanni R: Trisomy 17 as a marker for a subset of noninvasive thyroid nodules with focal features of papillary carcinoma: cytogenetic and molecular analysis of 62 cases and correlation with histological findings. J Clin Endocrinol Metab 2008, 93: 177–181.CrossRefPubMed Frau DV, Lai ML, Caria P, Dettori T, Coni P, Faa G, Morandi L, Tallini G, Vanni R: Trisomy 17 as a marker for a subset of noninvasive thyroid nodules with focal features of papillary carcinoma: cytogenetic and molecular analysis of 62 cases and correlation with histological findings. J Clin Endocrinol Metab 2008, 93: 177–181.CrossRefPubMed
29.
go back to reference Castro P, Rebocho AP, Soares RJ, Magalhaes J, Roque L, Trovisco V, Vieira de Castro I, Cardoso-de-Oliveira M, Fonseca E, Soares P, Sobrinho-Simoes M: PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 2006, 91: 213–220. 10.1210/jc.2005-1336CrossRefPubMed Castro P, Rebocho AP, Soares RJ, Magalhaes J, Roque L, Trovisco V, Vieira de Castro I, Cardoso-de-Oliveira M, Fonseca E, Soares P, Sobrinho-Simoes M: PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 2006, 91: 213–220. 10.1210/jc.2005-1336CrossRefPubMed
30.
go back to reference Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Maximo V, Botelho T, Moreira S, Meireles AM, et al.: Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 2005, 446: 589–595. 10.1007/s00428-005-1236-0CrossRefPubMed Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, Maximo V, Botelho T, Moreira S, Meireles AM, et al.: Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 2005, 446: 589–595. 10.1007/s00428-005-1236-0CrossRefPubMed
31.
go back to reference Nikiforov YE, Nikiforova MN: Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011, 7: 569–580. 10.1038/nrendo.2011.142CrossRefPubMed Nikiforov YE, Nikiforova MN: Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011, 7: 569–580. 10.1038/nrendo.2011.142CrossRefPubMed
32.
go back to reference Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE, Vasko VV, Saji M, et al.: Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009, 27: 1675–1684. 10.1200/JCO.2008.18.2717CrossRefPubMedPubMedCentral Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE, Vasko VV, Saji M, et al.: Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009, 27: 1675–1684. 10.1200/JCO.2008.18.2717CrossRefPubMedPubMedCentral
33.
go back to reference Gauchotte G, Philippe C, Lacomme S, Leotard B, Wissler MP, Allou L, Toussaint B, Klein M, Vignaud JM, Bressenot A: BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis. Pathology 2011, 43: 447–452. 10.1097/PAT.0b013e3283486178CrossRefPubMed Gauchotte G, Philippe C, Lacomme S, Leotard B, Wissler MP, Allou L, Toussaint B, Klein M, Vignaud JM, Bressenot A: BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis. Pathology 2011, 43: 447–452. 10.1097/PAT.0b013e3283486178CrossRefPubMed
34.
go back to reference Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R, Sobrinho-Simoes M: BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003, 22: 4578–4580. 10.1038/sj.onc.1206706CrossRefPubMed Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Maximo V, Botelho T, Seruca R, Sobrinho-Simoes M: BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003, 22: 4578–4580. 10.1038/sj.onc.1206706CrossRefPubMed
35.
go back to reference Lima J, Trovisco V, Soares P, Maximo V, Magalhaes J, Salvatore G, Santoro M, Bogdanova T, Tronko M, Abrosimov A, et al.: BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 2004, 89: 4267–4271. 10.1210/jc.2003-032224CrossRefPubMed Lima J, Trovisco V, Soares P, Maximo V, Magalhaes J, Salvatore G, Santoro M, Bogdanova T, Tronko M, Abrosimov A, et al.: BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 2004, 89: 4267–4271. 10.1210/jc.2003-032224CrossRefPubMed
36.
go back to reference Roskoski R: RAF protein-serine/threonine kinases: structure and regulation. Biochem Biophys Res Commun 2010, 399: 313–317. 10.1016/j.bbrc.2010.07.092CrossRefPubMed Roskoski R: RAF protein-serine/threonine kinases: structure and regulation. Biochem Biophys Res Commun 2010, 399: 313–317. 10.1016/j.bbrc.2010.07.092CrossRefPubMed
37.
go back to reference Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP: Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 2009, 28: 2119–2123. 10.1038/onc.2009.73CrossRefPubMedPubMedCentral Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP: Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 2009, 28: 2119–2123. 10.1038/onc.2009.73CrossRefPubMedPubMedCentral
38.
go back to reference Eisenhardt AE, Olbrich H, Roring M, Janzarik W, Anh TN, Cin H, Remke M, Witt H, Korshunov A, Pfister SM, et al.: Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. Int J Cancer 2011, 129: 2297–2303. 10.1002/ijc.25893CrossRefPubMed Eisenhardt AE, Olbrich H, Roring M, Janzarik W, Anh TN, Cin H, Remke M, Witt H, Korshunov A, Pfister SM, et al.: Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. Int J Cancer 2011, 129: 2297–2303. 10.1002/ijc.25893CrossRefPubMed
39.
go back to reference Carta C, Moretti S, Passeri L, Barbi F, Avenia N, Cavaliere A, Monacelli M, Macchiarulo A, Santeusanio F, Tartaglia M, Puxeddu E: Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). Clin Endocrinol (Oxf) 2006, 64: 105–109. 10.1111/j.1365-2265.2005.02401.xCrossRef Carta C, Moretti S, Passeri L, Barbi F, Avenia N, Cavaliere A, Monacelli M, Macchiarulo A, Santeusanio F, Tartaglia M, Puxeddu E: Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)). Clin Endocrinol (Oxf) 2006, 64: 105–109. 10.1111/j.1365-2265.2005.02401.xCrossRef
40.
go back to reference Moretti S, Macchiarulo A, De Falco V, Avenia N, Barbi F, Carta C, Cavaliere A, Melillo RM, Passeri L, Santeusanio F, et al.: Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma. Oncogene 2006, 25: 4235–4240. 10.1038/sj.onc.1209448CrossRefPubMed Moretti S, Macchiarulo A, De Falco V, Avenia N, Barbi F, Carta C, Cavaliere A, Melillo RM, Passeri L, Santeusanio F, et al.: Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma. Oncogene 2006, 25: 4235–4240. 10.1038/sj.onc.1209448CrossRefPubMed
41.
go back to reference Hou P, Liu D, Xing M: Functional characterization of the T1799–1801del and A1799–1816ins BRAF mutations in papillary thyroid cancer. Cell Cycle 2007, 6: 377–379. 10.4161/cc.6.3.3818CrossRefPubMed Hou P, Liu D, Xing M: Functional characterization of the T1799–1801del and A1799–1816ins BRAF mutations in papillary thyroid cancer. Cell Cycle 2007, 6: 377–379. 10.4161/cc.6.3.3818CrossRefPubMed
42.
go back to reference De Falco V, Giannini R, Tamburrino A, Ugolini C, Lupi C, Puxeddu E, Santoro M, Basolo F: Functional characterization of the novel T599I-VKSRdel BRAF mutation in a follicular variant papillary thyroid carcinoma. J Clin Endocrinol Metab 2008, 93: 4398–4402. 10.1210/jc.2008-0887CrossRefPubMed De Falco V, Giannini R, Tamburrino A, Ugolini C, Lupi C, Puxeddu E, Santoro M, Basolo F: Functional characterization of the novel T599I-VKSRdel BRAF mutation in a follicular variant papillary thyroid carcinoma. J Clin Endocrinol Metab 2008, 93: 4398–4402. 10.1210/jc.2008-0887CrossRefPubMed
43.
go back to reference Chiosea S, Nikiforova M, Zuo H, Ogilvie J, Gandhi M, Seethala RR, Ohori NP, Nikiforov Y: A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma. Endocr Pathol 2009, 20: 122–126. 10.1007/s12022-009-9073-3CrossRefPubMed Chiosea S, Nikiforova M, Zuo H, Ogilvie J, Gandhi M, Seethala RR, Ohori NP, Nikiforov Y: A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma. Endocr Pathol 2009, 20: 122–126. 10.1007/s12022-009-9073-3CrossRefPubMed
Metadata
Title
BRAF mutations in thyroid tumors from an ethnically diverse group
Authors
Hans-Juergen Schulten
Sherine Salama
Zuhoor Al-Mansouri
Reem Alotibi
Khalid Al-Ghamdi
Osman Abdel Al-Hamour
Hassan Sayadi
Hosam Al-Aradati
Adel Al-Johari
Etimad Huwait
Mamdooh Gari
Mohammed Hussain Al-Qahtani
Jaudah Al-Maghrabi
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Hereditary Cancer in Clinical Practice / Issue 1/2012
Electronic ISSN: 1897-4287
DOI
https://doi.org/10.1186/1897-4287-10-10

Other articles of this Issue 1/2012

Hereditary Cancer in Clinical Practice 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine